Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF).
Vertex Pharmaceuticals stock last closed at $515.02, down 1.08% from the previous day, and has increased 21.95% in one year. It has overperformed other stocks in the Biotechnology industry by 1.17 percentage points. Vertex Pharmaceuticals stock is currently +24.92% from its 52-week low of $412.27, and -9.43% from its 52-week high of $568.67.
There are currently 253.54M VRTX shares outstanding. The market capitalization of VRTX is $130.58B. In the last 24 hours, 1.71M VRTX shares were traded.
You will need an online brokerage account to access the NASDAQ market and buy VRTX shares.
Based on our research, eToro is the best online stock brokerage. eToro gives you:
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked the best brokerage, the next step is to fill out some personal info so you are able to invest in VRTX stock today.
Now that you've finished signing up on the best stock market app for beginners, you need to deposit funds:
Watch the walkthrough below for more details transferring funds into your new brokerage account.
After you have selected the best place to buy Vertex Pharmaceuticals stock, it's important to research their stock before you buy, so you can comprehend the risk and opportunity.
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on VRTX's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge VRTX's intrinsic value.
Using relative valuations ratios:
You can access more valuation research on VRTX's stock here.
Out of 14 sell side analysts who give ratings on VRTX, the consensus analyst rating on VRTX is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Michael Yee, a top 10% analyst from UBS maintains VRTX with a strong buy rating and raises their VRTX price target from $615.00 to $640.00, on Nov 3, 2026.
Phil Nadeau, a top 12% analyst from TD Cowen maintains VRTX with a strong buy rating and raises their VRTX price target from $550.00 to $575.00, on Nov 3, 2026.
Mohit Bansal, a top 11% analyst from Wells Fargo maintains VRTX with a strong buy rating and raises their VRTX price target from $550.00 to $650.00, on Nov 3, 2026.
Wells Fargo's Mohit Bansal raised their price target on Vertex Pharmaceuticals (NASDAQ: VRTX) by 18.2% from $550 to $650 on 2026/11/03. The analyst maintained their Strong Buy rating on the stock.
Vertex Pharmaceuticals reported its Q3 2026 earnings.
Based on management's encouraging tone on Pove CMC and label issues, Bansal said they are comfortable regarding the November 30th PDUFA.
According to the analyst, Vertex Pharmaceuticals is starting to look like a good long-term investment with the removal of CF competition overhang and advancements in its pipeline.
For Q3 2026, Vertex Pharmaceuticals reported:
For FY 2026, management guided:
CEO Reshma Kewalramani, M.D. commented: “Vertex delivered excellent Q3 results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.
“With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.”
Brian Abrahams, a top 16% analyst from RBC Capital maintains VRTX with a buy rating and raises their VRTX price target from $576.00 to $600.00, on Nov 3, 2026.
Paul Matteis, a bottom 10% analyst from Stifel Nicolaus maintains VRTX with a hold rating and raises their VRTX price target from $500.00 to $563.00, on Nov 3, 2026.
You can dig deeper into what analysts are projecting on the Vertex Pharmaceuticals stock forecast page.
Last year, VRTX earnings were $3.98B. In the last five year, VRTX's earnings have gone up by 13.23% per year. This was slower than the Biotechnology industry average of 74.13%.
Last year, VRTX revenue was $12.95B. Over the past five year, VRTX's revenue has grown by 12.68% per year. This was slower than the Biotechnology industry average of 30.09%.
Dive into VRTX's earnings and revenue performance here.
In the last 12 months, executives and large shareholders at VRTX have sold more shares than they have bought.
Sangeeta N. Bhatia, Director of VRTX, was the latest VRTX insider to sell. They sold $148,470.06 worth of VRTX shares on Nov 16, 2026.
Learn more about who owns VRTX stock here.
No, Vertex Pharmaceuticals doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
There are two primary types of orders:
Hit the Open Trade button and your broker will place your order.
If you want additional help with investing in stocks on eToro, click the how to video below:
Now that you own some shares in VRTX, you'll want to stay up-to-date on your investment.
Create a watchlist to monitor your VRTX stock.
To summarize, here are the 6 steps for buying Vertex Pharmaceuticals stock:
If you need a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep track of your investment in Vertex Pharmaceuticals, click below.